Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024
Conference Call Scheduled for Wednesday, April 24 at 4:30 p.m. Eastern Time
SAN DIEGO, April 17, 2024 /PRNewswire/ — Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the first quarter 2024 after the market close on Wednesday, April 24, 2024.